The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bermuda,
Eloquently put! I was wondering how to make that point all evening!
ATB
BOJO - there are a handful of others also targeting spike and nucleocapsid proteins and data from any of them validating nucleocapsid as a target can only make Covidity more attractive to potential partners.
BOJO
Definitely! In all aspects of life they say knowledge is key.
Thanks Burble / Bermuda / Ivy
Good to have your views. It is certainly worth investigating the competition don’t you think? Certainly for a novice like me anyhow, it helps me understand the whole space whilst not necessarily changing my conviction about Scancell.
ATB
This is a good article to read explaining some of this. https://www.nature.com/articles/s41565-021-00946-9 - specifically the section entitled 'The case of adenoviruses'
Ivy,
There will undoubtedly be an immune response against the vector - as a foreign body within the patient, it is highly likely that the patient develops an immune response targetting the vector. Obviously many adenovirus strains may be deployed, but it is a phenomenon that is seen with this type of vaccine delivery system. There are ways this can be minimised through things like surface engineering, but it still is a possibility which isn't faced with other delivery mechanisms.
Some of the older papers on this saw that when an adenovirus vector was delivered intramuscularly, a neutralising antibody response peaked between two to three weeks after delivery. Interesting, this neutralising effect was only prohibitive of successful delivery when delivered intravenously not intramuscularly. One of the other things that is a compounding factor is background anti-adenovirus immunity. Hence why generally the viruses used are non-human as there is then limited chance of there being pre-existing immunity.
Slightly different target, but the same goes for oncolytic virus therapy. Repeated cycles of enadenotucirev (a group B adenovirus) was conducted in clinical trials. This found that activity of the virus was lower with each repeat cycle (https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0510-7) 'However, the virus activity was lower at cycle 2 than cycle 1 and declined further by cycle 3, suggesting that the overall affinity of the antibody response might be increasing, leading to an increase in overall neutralizing activity. However, it is not known whether, or to what extent these antibodies may interfere with virus delivery to and activity within tumors.'
Violindog,
I am with you 100%! But we do need data for covidity and the first sniff could be 8 to 12 weeks away yet. I could name 5 covid ‘joke’ stocks right off the bat that have a flying share price based on pure sentiment. I could name another 5 that have since crumbled to nothing after being over hyped. Isn't that just annoying! At least when we move up it will be based on fact and that means we will stay up.
ATB.
burble,
Apparently ImmunityBio have circumvented the issue of anti vector immunity by genetically engineering to delete genes encoding for certain proteins - of course yet to be proven in the clinic.
Hi Burble,
I did not realise that the immune response was against the Vector as well and that it had a longer effect.
I have been selling Vector Viral Vaccines for a long time and the platform used is identical to the ChAd one in terms of technology.
The Vector is not affected by either the CMR or Humoral response as essentially it is simply to deliver the DNA gag and envelope part into the target and then just naturally disappears as I would expect a Chimpanzee Adenovirus to do so within a human.
Just very interested in your thoughts as you know a lot more about this space than me
Yes, polly-varient vaccines were mentioned. I just can't believe that we have a vaccine candidate in trial, that is UK developed, and initial results are literally within weeks..... and yet we have had no recent press coverage and a flat share price.
Incredible.
Whilst the world does need better vaccines, it is important to note the benefits of different platform technologies. Immunity Bio bases it's vaccines on a human adenovirus platform - similar to the astra zeneca vaccine. Whilst this has benefits over mRNA vaccines for things like cold chain storage, size of genetic material delivered etc. It does have drawbacks if there is requirement to repeat dose as the body mounts an immune response against the vector leading to reductions in efficacy.
Nucleotide based vaccines (mRNA or DNA) do not have this drawback. So whilst the world needs multiple vaccines, if we see waining immunity even in these second generation vaccines, IMHO I think there is more likelihood of the world coalescing behind second generation boosters based on mRNA or DNA technology than they will on adenovirus based platforms. So SCLP has plenty of opportunities for a shot at goal with Covidity, even in an ever increasingly crowded field.
Immunity Bio have 3 phase 1 candidates in trials for covid. Target S and N protein. They are a big concern that are looking at charging memory T cells, memory B cells and memory T +. Currently have 17 separate trials across cancer, HIV, covid etc. price has peaked at $50 this year, currently on my watch list @ $6.38.
https://immunitybio.com/pipeline/
Scroll down for covid candidates.
Definitely a mention of multi variant vaccines under development and their importance . Anyone else doing one apart from us.